A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice

Journal of Neural Transmission

Volumn 118, Issue 11, 2011, Pages 1535-1546

  Poleszak, Ewa ^a   Wlaź, Piotr ^b   Szewczyk, Bernadeta ^c   Wlaź, Aleksandra ^a   Kasperek, Regina ^a   Wróbel, Andrzej ^a   Nowak, Gabriel ^c,d  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^c INSTITUTE OF PHARMACOLOGY   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antidepressants; Forced swim test; Glycine site; Lesion; Mice; NMDA receptor

Indexed keywords

7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; CYCLOSERINE; FLUOXETINE; GLYCINE; IMIPRAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; REBOXETINE; SERINE; SEROTONIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; FORCED SWIMMING TEST; IMMOBILIZATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

ADRENERGIC AGONISTS; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; MALE; MICE; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN RECEPTOR AGONISTS; STRESS, PSYCHOLOGICAL; SWIMMING;

EID: 84855241691     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-011-0630-9     Document Type: Article

References (81)

1. Altamura CA, Mauri MC, Ferrara A, Moro AR, D'Andrea G, Zamberlan F (1993) Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 150:1731-1733 (Pubitemid 23325960)
2. Beardsley PM, Ratti E, Balster RL, Willetts J, Trist D (2002) The selective glycine antagonist gavestinel lacks phencyclidine-like behavioral effects. Behav Pharmacol 13:583-592 (Pubitemid 35387418)
3. Bechtholt-Gompf AJ, Smith KL, John CS, Kang HH, Carlezon WA Jr, Cohen BM, Öngür D (2011) CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy. Psychopharmacology (Berl) (in press) doi:10.1007/s00213-011-2169-8
4. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354 (Pubitemid 30109248)
5. Bordi F, Terron A, Reggiani A (1999) The neuroprotective glycine receptor antagonist GV150526 does not produce neuronal vacuolization or cognitive deficits in rats. Eur J Pharmacol 378:153-160 (Pubitemid 29356011)
6. Borsini F, Meli A (1988) Is the forced swimming test a suitable odel for revealing antidepressant activity? Psychopharmacology (Berl) 94:147-160 (Pubitemid 18040687)
7. Boulay D, Pichat P, Dargazanli G, Estenne-Bouhtou G, Terranova JP, Rogacki N, Stemmelin J, Coste A, Lanneau C, Desvignes C, Cohen C, Alonso R, Vige X, Biton B, Steinberg R, Sevrin M, Oury-Donat F, George P, Bergis O, Griebel G, Avenet P, Scatton B (2008) Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacol Biochem Behav 91:47-58
8. Danysz W, Parsons CG (1998) Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 50:597-664 (Pubitemid 29028813)
9. Emmett MR, Mick SJ, Cler JA, Rao TS, Iyengar S, Wood PL (1991) Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacology 30:1167-1171
10. Feyissa AM, Chandran A, Stockmeier CA, Karolewicz B (2009) Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. ProgNeuropsychopharmacol Biol Psychiatry 33:70-75
11. Hawkinson JE, Huber KR, Sahota PS, Han HH, Weber E, Whitehouse MJ (1997) The N-methyl-D-aspartate (NMDA) receptor glycine site antagonist ACEA 1021 does not produce pathological changes in rat brain. Brain Res 744:227-234 (Pubitemid 27032339)
12. Hollister LE, Csernansky JG (1990) Clinical pharmacology of psychotherapeutic drugs. Churchill Livingstone, New York
13. Hood WF, Compton RP, Monahan JB (1989) D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett 98:91-95 (Pubitemid 19054324)
14. Karolewicz B, Stockmeier CA, Ordway GA (2005) Elevated levels fthe NR2C subunit of the NMDA receptor in the locus coeruleus in depression. Neuropsychopharmacology 30:1557-1567 (Pubitemid 41153128)
15. Karolewicz B, Szebeni K, Gilmore T, Macia?g D, Stockmeier CA, Ordway GA (2009) Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression. Int J Neuropsychopharmacol 12:143-153
16. Kemp JA, Leeson PD (1993) The glycine site of the NMDA receptor- five years on. Trends Pharmacol Sci 14:20-25 (Pubitemid 23034603)
17. Kemp JA, McKernan RM (2002) NMDA receptor pathways as drug targets. Nat Neurosci 5(Suppl):1039-1042 (Pubitemid 35247194)
18. Kendig IV, Charen S, Lepine LT (1956) Psychological side effects induced by cycloserine in the treatment of pulmonary tuberculosis. Am Rev Tuberc 73:438-441
19. Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH (1982) Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr 232:299-304 (Pubitemid 13124834)
20. Koe BK, Weissman A (1966) p-Chlorophenylalanine: a specific depletor of brain serotonin. J Pharmacol Exp Ther 154:499-516
21. Kroczka B, Zie?ba A, Dudek D, Pilc A, Nowak G (2000) Zinc exhibits an antidepressant-like effect in the forced swimming test in mice. Pol J Pharmacol 52:403-406
22. Kroczka B, Brański P, Pałkucha A, Pilc A, Nowak G (2001) Antidepressant-like properties of zinc in rodent forced swim test. Brain Res Bull 55:297-300 (Pubitemid 32722173)
23. Law AJ, Deakin JF (2001) Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 12:2971-2974 (Pubitemid 32882018)
24. Layer RT, Popik P, Olds T, Skolnick P (1995) Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL- 82.0715). Pharmacol Biochem Behav 52:621-627
25. Levine J, Panchalingam K, Rapoport A, Gershon S, McClure RJ, Pettegrew JW (2000) Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry 47:586-593 (Pubitemid 30169251)
26. Lewis WC, Calden G, Thurston JR, Gilson WE (1957) Psychiatric and neurological reactions to cycloserine in the treatment of tuberculosis. Dis Chest 32:172-182
27. Lipman JJ, Spencer PS (1980) Rapid intracerebroventricular injection assisted by an automatic syringe. J Pharmacol Methods 4:327-333 (Pubitemid 11125776)
28. Löscher W, Annies R, Hönack D (1993) Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neuronal activity and behavioural effects in rats. Eur J Pharmacol 242:263-274 (Pubitemid 23290392)
29. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK (2008) Cellular mechanisms underlying the antidepressant effects of ketamine: role of a-amino-3-hydroxy-5- methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63:349-352 (Pubitemid 351146651)
30. Maj J, Rogóz Z, Skuza G, Sowińska H (1992a) Effects of MK-801 and antidepressant drugs in the forced swimming test in rats. EurNeuropsychopharmacol 2:37-41
31. Maj J, Rogóz Z, Skuza G, Sowińska H (1992b) The effect of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in the forced swimming test. Pol J Pharmacol Pharm 44:337-346 (Pubitemid 23009661)
32. Maj J, Rogóz Z, Skuza G, Kołodziejczyk K (1994) Some central effects of kynurenic acid, 7-chlorokynurenic acid and 5, 7-dichloro-kynurenic acid, glycine site antagonists. Pol J Pharmacol 46:115-124 (Pubitemid 24250434)
33. Mathis P, Schmitt L, Benatia M, Granier F, Ghisolfi J, Moron P (1988) Plasma amino acid disturbances and depression. Encephale 14:77-82
34. Matsumoto K, Ojima K, Watanabe H (1995) Noradrenergic denervation attenuates desipramine enhancement of aggressive behavior in isolated mice. Pharmacol Biochem Behav 50:481-484
35. Mauri MC, Ferrara A, Boscati L, Bravin S, Zamberlan F, Alecci M, Invernizzi G (1998) Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 37: 124-129 (Pubitemid 28171767)
36. Mitani H, Shirayama Y, Yamada T, Kawahara R (2006) Plasma levels of homovanillic acid, 5-hydroxyindoleacetic acid and cortisol, and serotonin turnover in depressed patients. Prog europsychopharmacol Biol Psychiatry 30:531-534
37. Moryl E, Danysz W, Quack G (1993) Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 72:394-397 (Pubitemid 23188507)
38. Nowak G, Ordway GA, Paul IA (1995) Alterations in the N-methyl-aspartate(NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 675:157-164
39. Nowak G, Siwek M, Dudek D, Zie?ba A, Pilc A (2003) Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol J Pharmacol 55:1143-1147 (Pubitemid 38128954)
40. Nowak G, Partyka A, Pałkucha A, Szewczyk B, Wierońska JM, Dybała M, Metz M, Librowski T, Froestl W, Papp M, Pilc A (2006) Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. Br J Pharmacol 149:581-590 (Pubitemid 44658519)
41. Papp M, Moryl E (1996) Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression. Eur J Pharmacol 316:145-151 (Pubitemid 27008144)
42. Paul IA, Skolnick P (2003) Glutamate and depression: clinical and preclinical studies. Ann NY Acad Sci 1003:250-272 (Pubitemid 38083061)
43. Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA Jr (2009) Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry 65:181-184
44. Poleszak E (2007) Modulation of antidepressant-like activity of magnesium by serotonergic system. J Neural Transm 114:1129-1134 (Pubitemid 47313166)
45. Poleszak E, Szewczyk B, Ke?dzierska E, Wlaź P, Pilc A, NowakAbs (2004) Antidepressant- and anxiolytic-like activity of magnesiumin mice. Pharmacol Biochem Behav 78:7-12 (Pubitemid 38670508)
46. Poleszak E, Wlaź P, Ke?dzierska E, Radziwoń-Zaleska M, Pilc A, Fidecka S, Nowak G (2005a) Effects of acute and chronic treatment with magnesium in the forced swim test in rats. Pharmacol Rep 57:654-658
47. Poleszak E, Wlaź P, Szewczyk B, Ke?dzierska E, Wyska E, Librowski T, Szymura-Oleksiak J, Fidecka S, Pilc A, Nowak G (2005b) Enhancement of antidepressant-like activity by joint administration of imipramine and magnesium in the forced swim test: behavioral and pharmacokinetic studies in mice. Pharmacol Biochem Behav 81:524-529 (Pubitemid 40966798)
48. Poleszak E, Wlaź P, Ke?dzierska E, Nieoczym D, Wróbel A, Fidecka S, Pilc A, Nowak G (2007a) NMDA/glutamate mechanism of antidepressant-like action of magnesium in forced swim test in mice. Pharmacol Biochem Behav 88:158-164 (Pubitemid 350115999)
49. Poleszak E, Wlaź P, Wróbel A, Dybała M, Sowa M, Fidecka S, Pilc A, Nowak G (2007b) Activation of the NMDA/glutamate receptor complex antagonizes the NMDA antagonist-induced antidepressant-like effects in the forced swim test. Pharmacol Rep 59:595-600
50. Poleszak E, Szewczyk B, Wlaź A, Fidecka S, Wlaź P, Pilc A, Nowak G (2008) D-serine, a selective glycine/N-methyl-Daspartate receptor agonist, antagonizes the antidepressant-likeeffects of magnesium and zinc in mice. Pharmacol Rep 60:996-1000
51. Popik P, Kos T, Sowa-Kućma M, Nowak G (2008) Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology (Berl) 198:421-430
52. Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327-336 (Pubitemid 8225714)
53. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW (2008) An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-Daspartate antagonist, CP-101, 606, in patients with treatmentrefractory major depressive disorder. J Clin Psychopharmacol28:631-637
54. Price RB, Nock MK, Charney DS, Mathew SJ (2009) Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66:522-526
55. Przegaliński E, Tatarczyńska E, Dereń-Wesołek A, Chojnacka-Wójcik E (1997) Antidepressant-like effects of a partial agonistat strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist. Neuropharmacology 36:31-37 (Pubitemid 27115840)
56. Przegaliński E, Tatarczyńska E, Chojnacka-Wójcik E (1998) Anxiolytic and antidepressant-like effects of an antagonist at glycine B receptors. Pol J Pharmacol 50:349-354
57. Rickels K, Schweizer E (1990) Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 51(Suppl B):9-12
58. Rosenzweig-Lipson S, Beyer CE, Hughes ZA, Khawaja X, Rajarao SJ, Malberg JE, Rahman Z, Ring RH, Schechter LE (2007) Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 113:134-153 (Pubitemid 46017069)
59. Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, Mason GF (2004) Subtype-specific alterations of c-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 61:705-713 (Pubitemid 38890805)
60. Siwek M, Dudek D, Paul IA, Sowa-Kućma M, Zie?ba A, Popik P, Pilc A, Nowak G (2009) Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. J Affect Disord 118:187-195
61. Skolnick P (1999) Antidepressants for the new millennium. Eur J Pharmacol 375:31-40 (Pubitemid 29317590)
62. Skolnick P, Marvizón JC, Jackson BW, Monn JA, Rice KC, Lewin AH (1989) Blockade of N-methyl-D-aspartate induced convulsions by 1-aminocyclopropanecarboxylates. Life Sci 45:1647-1655 (Pubitemid 19275492)
63. Skolnick P, Miller R, Young A, Boje K, Trullas R (1992) Chronic treatment with 1-aminocyclopropanecarboxylic acid desensitizes behavioral responses to compounds acting at the N-methyl-Daspartate receptor complex. Psychopharmacology (Berl) 107:489-496
64. Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R (1996) Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 29:23-26 (Pubitemid 26072654)
65. Skolnick P, Popik P, Trullas R (2009) Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 30:563-569
66. Szewczyk B, Poleszak E, Sowa-Kućma M, Siwek M, Dudek D, Ryszewska-Pokraśniewicz B, Radziwoń-Zaleska M, Opoka W, Czekaj J, Pilc A, Nowak G (2008) Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action. Pharmacol Rep 60:588-589
67. Szewczyk B, Poleszak E, Wlaź P, Wróbel A, Blicharska E, Cichy A, Dybała M, Siwek A, Pomierny-Chamioło L, Piotrowska A, Brański P, Pilc A, Nowak G (2009) The involvement of serotonergic system in the antidepressant effect of zinc in the forced swim test. Prog Neuropsychopharmacol Biol Psychiatry 33:323-329
68. Szewczyk B, Poleszak E, Sowa-Kućma M, Wróbel A, Słotwiński S, Listos J, Wlaź P, Cichy A, Siwek A, Dybała M, Gołembiowska K, Pilc A, Nowak G (2010) The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test. Amino Acids 39:205-217
69. Trullas R, Skolnick P (1990) Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 185:1-10 (Pubitemid 20254891)
70. Vamvakides A (1998) D-cycloserine is active in the adult mouse and inactive in the aged mouse, in the forced swim test. Ann Pharm Fr 56:209-212 (Pubitemid 28446485)
71. Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R (1999) Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 60:400-406 (Pubitemid 29289729)
72. Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH (1990) D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res 510:158-160 (Pubitemid 20060820)
73. Westenberg HG (1999) Pharmacology of antidepressants: selectivity or multiplicity? J Clin Psychiatry 60(Suppl 17):4-8
74. Willetts J, Balster RL, Leander JD (1990) The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci 11:423-428 (Pubitemid 20344028)
75. Wood PL, Emmett MR, Rao TS, Mick S, Cler J, Iyengar S (1989) In vivo modulation of the N-methyl-D-aspartate receptor complex by D-serine: potentiation of ongoing neuronal activity as evidenced by increased cerebellar cyclic GMP. J Neurochem 3:979-981 (Pubitemid 19207403)
76. Wood PL, Hawkinson JE, Goodnough DB (1996) Formation of Dserine from L-phosphoserine in brain synaptosomes. J Neurochem 67:1485-1490 (Pubitemid 26314204)
77. Yan QS, Reith ME, Jobe PC, Dailey JW (1997) Dizocilpine (MK- 01) increases not only dopamine but also serotonin and norepinephrine transmissions in the nucleus accumbens as measured by microdialysis in freely moving rats. Brain Res 765:149-158 (Pubitemid 27374926)
78. Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, Charney DS, Manji HK (2004) An open-label trial of riluzole in patients with treatment-resistant major depression. m J Psychiatry 161:171-174 (Pubitemid 38419327)
79. Zarate CA Jr, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, Charney DS, Manji HK (2005) An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 57:430-432 (Pubitemid 40215774)
80. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006a) A randomized trial of an N-methyl-D-aspartate antagonist in treatmentresistant major depression. Arch Gen Psychiatry 63:856-864 (Pubitemid 44188478)
81. Zarate CA Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, Manji HK, Charney DS (2006b) A doubleblind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 163:153-155 (Pubitemid 43050119)